DDInter1955 DDInter119
Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages.
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Zafirlukast {u} (Compound) resembles {v} (Compound) Tolvaptan
Zafirlukast {u} (Compound) treats {v} (Disease) asthma
Zafirlukast {u} (Compound) binds {v} (Gene) CYSLTR2
Zafirlukast {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 2C9 Inhibitors
Zafirlukast {u} (Compound) causes {v} (Side Effect) Hyperbilirubinaemia
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Donepezil
Zafirlukast {u} may cause a minor interaction that can limit clinical effects when taken with {v} Citalopram
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bortezomib
Zafirlukast {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Zafirlukast (Compound) resembles Tolvaptan (Compound)
Zafirlukast (Compound) treats asthma (Disease)
Zafirlukast (Compound) binds CYSLTR2 (Gene)
Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class)
Zafirlukast (Compound) causes Hyperbilirubinaemia (Side Effect)
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Donepezil
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Citalopram
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib
Zafirlukast may lead to a major life threatening interaction when taken with Lomitapide